Indivior PLC
ISIN: GB00BN4HT335 | Ticker: INDV | LEI: 213800V3NCQTY7IED471
Country: United Kingdom
Indivior PLC is a leading pharmaceutical company that specializes in developing treatments for addiction and related mental health disorders. Founded in 1994, Indivior has since established itself as a global leader in the field of addiction treatment, with a presence in over 40 countries worldwide.
The company's products are primarily focused on treating opioid addiction, including the development of innovative medications that help patients manage withdrawal symptoms and reduce the risk of relapse. Indivior's portfolio includes a range of medications, including Suboxone, a prescription medication used to treat opioid dependence, and Perseris, an injectable medication used to treat schizophrenia.
1994
Served areaWorldwide
Headquarters234 Bath Road, SL1 4EE Slough – United Kingdom
| Line item in (usd) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 1,531,000,000.00 | 1,832,000,000.00 | 1,769,000,000.00 |
| Noncurrent Assets | N/A | 344,000,000.00 | 388,000,000.00 | 510,000,000.00 |
| Property Plant And Equipment | N/A | 60,000,000.00 | 58,000,000.00 | 54,000,000.00 |
| Deferred Tax Assets | N/A | 75,000,000.00 | 105,000,000.00 | 219,000,000.00 |
| Other Noncurrent Assets | N/A | 104,000,000.00 | 106,000,000.00 | 38,000,000.00 |
| Current Assets | N/A | 1,187,000,000.00 | 1,444,000,000.00 | 1,259,000,000.00 |
| Inventories | N/A | 93,000,000.00 | 95,000,000.00 | 114,000,000.00 |
| Trade And Other Current Receivables | N/A | 179,000,000.00 | 202,000,000.00 | 220,000,000.00 |
| Cash and cash equivalents | 1,060,000,000.00 | 858,000,000.00 | 1,102,000,000.00 | 774,000,000.00 |
| Current Investments | N/A | N/A | 0.00 | 119,000,000.00 |
| Other Current Assets | N/A | 50,000,000.00 | 32,000,000.00 | 27,000,000.00 |
| Equity | 209,000,000.00 | 82,000,000.00 | 203,000,000.00 | 51,000,000.00 |
| Issued Capital | N/A | 73,000,000.00 | 70,000,000.00 | 68,000,000.00 |
| Retained Earnings | N/A | 1,311,000,000.00 | 1,438,000,000.00 | 1,303,000,000.00 |
| Share Premium | N/A | 6,000,000.00 | 7,000,000.00 | 8,000,000.00 |
| Other Reserves | N/A | -1,295,000,000.00 | -1,295,000,000.00 | -1,295,000,000.00 |
| Capital Redemption Reserve | N/A | 0.00 | 3,000,000.00 | 6,000,000.00 |
| Liabilities | N/A | 1,449,000,000.00 | 1,629,000,000.00 | 1,718,000,000.00 |
| Noncurrent Liabilities | N/A | 850,000,000.00 | 825,000,000.00 | 699,000,000.00 |
| Noncurrent Provisions | N/A | 51,000,000.00 | 76,000,000.00 | 5,000,000.00 |
| Other Noncurrent Liabilities | N/A | 526,000,000.00 | 474,000,000.00 | 428,000,000.00 |
| Longterm Borrowings | N/A | 230,000,000.00 | 239,000,000.00 | 237,000,000.00 |
| Current Liabilities | N/A | 599,000,000.00 | 804,000,000.00 | 1,019,000,000.00 |
| Current Provisions | N/A | 38,000,000.00 | 5,000,000.00 | 303,000,000.00 |
| Trade And Other Current Payables | N/A | 524,000,000.00 | 720,000,000.00 | 617,000,000.00 |
| Current Tax Liabilities Current | N/A | 15,000,000.00 | 7,000,000.00 | 9,000,000.00 |
| Other Current Liabilities | N/A | 10,000,000.00 | 61,000,000.00 | 79,000,000.00 |
| Line item in (usd) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 647,000,000.00 | 791,000,000.00 | 901,000,000.00 |
| Other Income | 0.00 | 32,000,000.00 | 8,000,000.00 |
| Profit Loss From Operating Activities | -156,000,000.00 | 213,000,000.00 | -85,000,000.00 |
| Finance Income | 9,000,000.00 | 4,000,000.00 | 19,000,000.00 |
| Finance Costs | 26,000,000.00 | 27,000,000.00 | 29,000,000.00 |
| Profit Loss Before Tax | -173,000,000.00 | 190,000,000.00 | -95,000,000.00 |
| Income Tax Expense Continuing Operations | -25,000,000.00 | -15,000,000.00 | -42,000,000.00 |
| Profit (loss) | -148,000,000.00 | 205,000,000.00 | -53,000,000.00 |
| Line item in (usd) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -148,000,000.00 | 205,000,000.00 | -53,000,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -16,000,000.00 | -3,000,000.00 | -25,000,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | -5,000,000.00 | -3,000,000.00 | -3,000,000.00 |
| Adjustments For Sharebased Payments | N/A | 8,000,000.00 | 11,000,000.00 | 16,000,000.00 |
| Cash Flows From Used In Operations | N/A | -148,000,000.00 | 395,000,000.00 | 63,000,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 20,000,000.00 | 18,000,000.00 | 24,000,000.00 |
| Interest Received Classified As Operating Activities | N/A | 9,000,000.00 | 1,000,000.00 | 15,000,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 34,000,000.00 | 48,000,000.00 | 57,000,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -193,000,000.00 | 353,000,000.00 | -4,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 4,000,000.00 | 4,000,000.00 | 5,000,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 0.00 | 30,000,000.00 | 1,000,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -4,000,000.00 | -14,000,000.00 | -223,000,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 250,000,000.00 | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 4,000,000.00 | 236,000,000.00 | 3,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 7,000,000.00 | 8,000,000.00 | 9,000,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -10,000,000.00 | -94,000,000.00 | -100,000,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -207,000,000.00 | 245,000,000.00 | N/A |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 5,000,000.00 | -1,000,000.00 | -1,000,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | N/A | 244,000,000.00 | -328,000,000.00 |
| Cash and cash equivalents | 1,060,000,000.00 | 858,000,000.00 | 1,102,000,000.00 | 774,000,000.00 |
Please note that some sums might not add up.
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| Balyasny Asset Management (UK) LLP | 0.73% | 20.12.23 |
| GLG Partners LP | 0.53% | 17.11.23 |
| Total | 1.26% |
GB00BN4HT335
LEI213800V3NCQTY7IED471
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryFTSE 250
Main Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.